Sensitive detection of plasma interferon regulatory factor-5 (IRF5) by solid-phase proximity ligation assay validates IRF5 high and low subgroups in patients with systemic lupus erythematosus
Open Access
- 9 December 2025
- journal article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (3) , 184-190
Abstract
Interferon regulatory factor 5 (IRF5) plays a central role in interferon-mediated inflammation and is implicated in autoimmune diseases, including systemic lupus erythematosus (SLE). Detecting IRF5 in plasma is challenging due to its low circulating levels, highlighting the need for a highly sensitive and quantitative assay. This study aimed to develop such an assay, validate the existence of previously identified IRF5 high and low subgroups in SLE, and support the potential of IRF5 as a biomarker in precision medicine. We established a solid-phase proximity ligation assay (SP-PLA) for IRF5 detection using a commercially available polyclonal antibody, which was benchmarked against two in-house recombinant antibodies. A linear calibration curve was generated using recombinant IRF5 protein (range 0.01-100 pg/µL), with a limit of detection between 0.01 and 0.05 pg/µL. EDTA-plasma samples from three SLE subgroups (n = 25 per group) were analysed. IRF5 was detectable in all SLE plasma samples using SP-PLA (mean 0.63 pg/µL; sd 1.92 pg/µL; maximum 13.54 pg/µL). The IRF5 high SLE subgroup showed significantly higher IRF5 plasma levels than the IRF5 low SLE subgroup (Dunn's post-hoc test, adjusted p < 0.05). The SP-PLA enabled sensitive and specific detection of low-level IRF5 in plasma and confirmed the presence of IRF5 high and low subgroups in SLE using a quantitative method. These findings support the potential of IRF5 as a biomarker, but validation in independent cohorts is required. The assay may facilitate patient stratification in future research and precision medicine approaches targeting the interferon pathway.Keywords
Funding Information
- Reumatikerförbundet (R-860021)
- Innovative Medicines Initiative (115766)
This publication has 11 references indexed in Scilit:
- Generation and validation of recombinant antibodies to study human aminoacyl-tRNA synthetasesJournal of Biological Chemistry, 2020
- Type I interferon antagonists in clinical development for lupusExpert Opinion on Investigational Drugs, 2020
- Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialThe Lancet Rheumatology, 2019
- Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectivesArthritis Research & Therapy, 2019
- Therapeutic Targeting of IRFs: Pathway-Dependence or Structure-Based?Frontiers in Immunology, 2018
- Advances and challenges in targeting IRF5, a key regulator of inflammationThe FEBS Journal, 2018
- Parallel Protein Detection by Solid‐Phase Proximity Ligation Assay with Real‐Time PCR or SequencingCurrent Protocols in Molecular Biology, 2015
- IRF5-mediated signaling and implications for SLEClinical Immunology, 2014
- Solid-phase proximity ligation assays for individual or parallel protein analyses with readout via real-time PCR or sequencingNature Protocols, 2013
- Sensitive Plasma Protein Analysis by Microparticle-based Proximity Ligation AssaysMolecular & Cellular Proteomics, 2010